Intriguingly, our results demonstrated that hypomethylation of MXD3 mediated dysfunctional T-cell phenotypes and shorter life durations of brain cancer, melanoma, metastatic melanoma, leukemia, breast cancer, and kidney renal clear cell carcinoma (KIRC) cohorts. Here, MXD3 is linked to leukemia.